Health and Fitness Health and Fitness
Mon, April 18, 2011
[ Mon, Apr 18th 2011 ] - Market Wire
00 a.m. ET
Sun, April 17, 2011
Fri, April 15, 2011
Thu, April 14, 2011
Wed, April 13, 2011
Tue, April 12, 2011
Mon, April 11, 2011
Sun, April 10, 2011
Sat, April 9, 2011
Fri, April 8, 2011
Thu, April 7, 2011
[ Thu, Apr 07th 2011 ] - Market Wire
Volunteering Does a Body Good
Wed, April 6, 2011
Tue, April 5, 2011
Mon, April 4, 2011
Sun, April 3, 2011
Sat, April 2, 2011
Fri, April 1, 2011
Thu, March 31, 2011
Wed, March 30, 2011
Tue, March 29, 2011

AVI BioPharma to Present Company Overview at the BioCentury Future Leaders in the Biotech Industry Conference


//health-fitness.news-articles.net/content/2011/ .. -leaders-in-the-biotech-industry-conference.html
Published in Health and Fitness on Friday, April 8th 2011 at 9:06 GMT by Market Wire   Print publication without navigation


BOTHELL, WA--(Marketwire - April 8, 2011) - AVI BioPharma (NASDAQ: [ AVII ]), a developer of RNA-based therapeutics, announced today that the company is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference in New York City on Friday, April 15, at 1:30 p.m. Eastern Time. Chris Garabedian, AVI's president and CEO, will provide a company overview.

The presentation will be Webcast live under the events section of AVI's website at [ www.avibio.com ] and will be archived there following the presentation. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About AVI BioPharma
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses. For more information, visit [ www.avibio.com ].


Publication Contributing Sources